AbbVie Inc. (ABBV)

78.69
NYSE : Health Technology
Prev Close 78.95
Day Low/High 78.21 / 79.34
52 Wk Low/High 73.81 / 100.23
Avg Volume 5.24M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 116.71B
EPS 3.70
P/E Ratio 22.05
Div & Yield 4.28 (5.17%)
These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

U.S. stock futures fall as earnings from Amazon.com disappoint.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

AbbVie Reaches All-Time Highs

AbbVie Reaches All-Time Highs

Today's breakout could carry the stock sharply higher.

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Remarkable data was released from Vertex's triple regiment combination trials.

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

Tech companies aren't the only ones seeing their shares rise this year.

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in Healthcare

What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in Healthcare

Players include Apple, Google, Microsoft and Samsung.

Samsung Could Sell More Drugs

Samsung Could Sell More Drugs

Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher

AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher

AbbVie's June rally has now driven shares past the 2016 high.

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.

Wall Street Weighs In on Athenahealth's Strategic Options

Wall Street Weighs In on Athenahealth's Strategic Options

Elliott's previous successes in the healthcare space bode well for its chances at athena.

AbbVie Stock Lower on Humira Patent Ruling

AbbVie Stock Lower on Humira Patent Ruling

The drug is responsible for more than 60% of AbbVie's top line.

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on AbbVie, Broadcom, Enbridge Energy Partners, and Commercial Vehicle Group.

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)

Jim Cramer says investors are migrating toward sectors likely to have the biggest upside in the second half.

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Between Amazon and Alphabet; Oil Dominoes: Jim Cramer's View

Cramer shares his views on which is better: Amazon or Alphabet, and discusses the domino effect when oil falls.

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Domino Effect of Falling Oil Prices: Cramer's 'Mad Money' Recap (Thursday 4/27/17)

Jim Cramer says this market is strong enough to withstand falling oil prices and a tax plan that will face a lot of obstacles.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Cramer: When Oil Falls, These Dominoes Get Hit

Cramer: When Oil Falls, These Dominoes Get Hit

It doesn't look like Washington will be much help.

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

S&P 500, Dow Hold Slight Gains as Positive Earnings Counter Oil Slump

Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.

TheStreet Quant Rating: B- (Buy)